Reported Sunday, Mesoblast Q1 Revenue Surges To $20.6M As Ryoncil Net Sales Jump 69% Driven By Wider Physician Adoption And Reimbursement
Benzinga Newsdesk 1 year ago
News
Revenue from cell therapy products was US$20.6 million, up from US$12.9 million in the previous quarter ended June 30, 2025, and over ten times greater than prior corresponding Q1 FY25.Revenue growth for the September
- Revenue from cell therapy products was US$20.6 million, up from US$12.9 million in the previous quarter ended June 30, 2025, and over ten times greater than prior corresponding Q1 FY25.
- Revenue growth for the September 2025 quarter compared with the June 2025 quarter was driven by a 66% increase in Ryoncil® gross sales to US$21.9 million and 69% increase in net sales to US$19.1 million after 12.7% gross to net adjustment.
- US$14.9 million net operating cash spend, a reduction of US$1.7 million versus the prior quarter ended June 30.
- US$145 million cash on hand at September 30, 2025.